US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
GeoVax Labs, Inc. - Common Stock
(NQ:
GOVX
)
0.3201
-0.0021 (-0.65%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GeoVax Labs, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
GeoVax Announces a Warrant Inducement Transaction
May 07, 2026
ATLANTA, GA - May 7, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant...
Via
TheNewswire.com
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization
Via
TheNewswire.com
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 29, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 02, 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen
Via
NewMediaWire
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 02, 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen
Via
TheNewswire.com
GeoVax Provides Update on GEO-MVA Program
March 25, 2026
Clinical Product Release Testing Completed in Support of Pivotal Phase 3 Trial
Via
TheNewswire.com
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 29, 2026
Near-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation
Via
TheNewswire.com
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
April 27, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
April 27, 2026
Positioned to Enhance Efficacy of Checkpoint Inhibitors and Next-Generation Oncology Modalities Across Solid Tumors
Via
TheNewswire.com
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 15, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 15, 2026
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)
Via
TheNewswire.com
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine
March 11, 2026
Program Reaches Strategic Inflection Point as GEO-MVA Advances Toward Pivotal Phase 3 Study
Via
TheNewswire.com
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 14, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Economy
Supply Chain
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 14, 2026
Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide
Via
TheNewswire.com
Topics
Economy
Supply Chain
GeoVax Announces a Warrant Inducement Transaction
March 31, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
March 31, 2026
ATLANTA, GA - March 31, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,...
Via
TheNewswire.com
GeoVax Provides Update on GEO-MVA Program
March 25, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
March 12, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
March 12, 2026
Peer-Reviewed Article Describes Clinical and Immunologic Rationale for Dual-Antigen MVA-Based Vaccine Designed to Address Limitations of First-Generation COVID-19 Vaccines in Highly Vulnerable...
Via
TheNewswire.com
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine
March 11, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors
February 24, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors
February 24, 2026
Members Bring Deep Expertise in Immuno-Oncology, Translational Medicine, and Checkpoint Inhibitor Combination Strategies
Via
TheNewswire.com
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology
February 18, 2026
License Strengthens GeoVax’s Immuno-Oncology Strategy and Expands Intellectual Property Foundation for Combination Therapies Across Solid Tumors
Via
TheNewswire.com
Topics
Intellectual Property
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology
February 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over
February 17, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over
February 17, 2026
Company Highlights GEO-MVA Manufacturing Readiness and Clear Clinical Pathway to Support Global Supply Diversification
Via
TheNewswire.com
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
February 13, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
February 13, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Friday's session.
↗
February 13, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
